Skip to content
DataLookout
Menu

NCT07797426

A Study of RT023 in Patients With Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 12, 2026 to Sep 16, 2026
    • Study sites: 0 to 1
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

DLT
Timeframe: Up to 12 months
Adverse Events
Timeframe: Up to 36 months
MTD
Timeframe: Up to 12 months
RP2D
Timeframe: Up to 12 months
ORR
Timeframe: Up to 36 months
SAEs
Timeframe: Up to 36 months

Secondary (8)

DoR
DCR
PFS
OS
Cmax
Show 3 moreShow less
Immunogenicity
AUC0-t
t1/2

Arms and interventions

dose escalationExperimental

Participants with advanced solid tumors will receive escalating doses of RT023.

dose expansionExperimental

Participants with advanced solid tumors will receive RT023 at doses which are expected to be efficacious and have completed dose escalation.

clinical expansionExperimental

Participants with target tumors will receive RT023 at the Recommended Phase 2 dose (RP2D).

Drugs: RT023

Sites

1 site in 1 country

  • Shanghai East HospitalShanghai, Shanghai Municipality, China